Skip to Main Content

Paper Details

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Clin Cancer Res
18
2021
-CAD fusion, -GOPC fusion, ALK, ALK L1196Q, BRAF, BRAF V600E, BRAF wild-type tumors, CAD, Colorectal Cancers, GOPC, L1196Q, Lynch syndrome, MLH1 promoter, MMR, MMR-D, MMR-D colorectal cancer, MMR-D colorectal cancers, MMR-D tumors, MSS colorectal cancer, RAS, RAS and BRAF wild-type tumors, ROS1, RTK, RTK fusions, RTKs, Receptor Tyrosine Kinase Fusions, Receptor tyrosine kinase fusions, Tyrosine, V600E, alectinib, cancer, cancers, colorectal, colorectal cancer, colorectal cancers, crizotinib, entrectinib, mismatch repair-deficient (MMR-D) colorectal, oncogenic fusions, patient, patients, sessile, sessile serrated polyp, tumors
Author NameAffiliation
Matthew DucarCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute
Aaron R ThornerCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute
Laura E MacConaillBrigham and Women's Hospital, Harvard Medical School
Azra H LigonDivision of Clinical Cytogenetics, Brigham and Women's Hospital, Harvard Medical School
Matthew MeyersonDana-Farber Cancer Institute, Harvard Medical School
Matthew MeyersonBroad Institute of MIT and Harvard
Matthew MeyersonDana-Farber Cancer Institute, Harvard Medical School
Matthew MeyersonBroad Institute of MIT and Harvard
Andrew D CherniackDana-Farber Cancer Institute, Harvard Medical School
Andrew D CherniackBroad Institute of MIT and Harvard
Andrew D CherniackDana-Farber Cancer Institute, Harvard Medical School
Andrew D CherniackBroad Institute of MIT and Harvard
Jason L HornickBrigham and Women's Hospital, Harvard Medical School
  • 1 - 13

Datasets

Release 1.2